Abstract:Purpose: Glioblastoma (GBM) is a fatal primary malignant brain tumor. GBM stem cells (GSC) contribute to resistance to the DNA-damaging chemotherapy, temozolomide. The epidermal growth factor receptor (EGFR) displays genomic alterations enabling DNA repair mechanisms in half of GBMs. We aimed to investigate EGFR/DNA combi-targeting in GBM.Experimental Design: ZR2002 is a "combi-molecule" designed to inflict DNA damage through its chlorethyl moiety and induce irreversible EGFR tyrosine kinase inhibition. We ass… Show more
“…As shown in Figure 2, the conversion of the combi-molecule AL530 into its two bioactive components (DNA damage species and MEK inhibitor) was largely accelerated at an acidic pH. The pH rate profile also indicated that AL530 is hydrolyzed at a pH range between 5.5-6.5, which is within the range of pH reported for the tumor microenvironment [12][13][14]. The results are in line with the cleavage mechanism proposed in Scheme 1, wherein the pH rate profile clearly suggests that N-protonation of the tetrahedral intermediate is the rate determining step of the reaction.…”
Section: Kinetics Of Al530 Hydrolysis At Variable Ph and Temperaturesupporting
The clinical use of cytotoxic agents is plagued by systemic toxicity. We report a novel approach that seeks to design a “combi-molecule” to behave as an alkylating agent on its own and to undergo acid-catalyzed conversion to two bioactive species at a pH range akin to that of a tumor microenvironment: an AL530 prototype was synthesized and we studied its ability to release a chlorambucil analogue (CBL-A) plus a potent mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor (PD98059) at different pHs in buffered solutions, plasma and tumors. Its potency was compared in vitro with CBL+PD98059 (SRB assay) and in vivo in a xenograft model. Its target modulation was studied by western blotting and immunohistochemistry. AL530 released PD98059+CBL-A at mild acidic pH and in vitro was fivefold more potent than CBL and three-to-fivefold more potent than CBL+PD98059. In vivo it released high levels of PD98059 in tumors with a tumor/plasma ratio of five. It induced γ-H2AX phosphorylation and blocked pErk1,2, indirectly indicating its ability to damage DNA and modulate MEK. It induced significant tumor delay and less toxicity at unachievable doses for CBL and CBL+PD98059. We demonstrated the feasibility of a pH-labile combi-molecule capable of delivering high MEK inhibitor concentration in tumors, damaging DNA therein, and inducing tumor growth delay.
“…As shown in Figure 2, the conversion of the combi-molecule AL530 into its two bioactive components (DNA damage species and MEK inhibitor) was largely accelerated at an acidic pH. The pH rate profile also indicated that AL530 is hydrolyzed at a pH range between 5.5-6.5, which is within the range of pH reported for the tumor microenvironment [12][13][14]. The results are in line with the cleavage mechanism proposed in Scheme 1, wherein the pH rate profile clearly suggests that N-protonation of the tetrahedral intermediate is the rate determining step of the reaction.…”
Section: Kinetics Of Al530 Hydrolysis At Variable Ph and Temperaturesupporting
The clinical use of cytotoxic agents is plagued by systemic toxicity. We report a novel approach that seeks to design a “combi-molecule” to behave as an alkylating agent on its own and to undergo acid-catalyzed conversion to two bioactive species at a pH range akin to that of a tumor microenvironment: an AL530 prototype was synthesized and we studied its ability to release a chlorambucil analogue (CBL-A) plus a potent mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitor (PD98059) at different pHs in buffered solutions, plasma and tumors. Its potency was compared in vitro with CBL+PD98059 (SRB assay) and in vivo in a xenograft model. Its target modulation was studied by western blotting and immunohistochemistry. AL530 released PD98059+CBL-A at mild acidic pH and in vitro was fivefold more potent than CBL and three-to-fivefold more potent than CBL+PD98059. In vivo it released high levels of PD98059 in tumors with a tumor/plasma ratio of five. It induced γ-H2AX phosphorylation and blocked pErk1,2, indirectly indicating its ability to damage DNA and modulate MEK. It induced significant tumor delay and less toxicity at unachievable doses for CBL and CBL+PD98059. We demonstrated the feasibility of a pH-labile combi-molecule capable of delivering high MEK inhibitor concentration in tumors, damaging DNA therein, and inducing tumor growth delay.
“…However, resistant tumor cell subsets promoting recurrence, rapidly emerge. Although these cells, presenting CSC features, do frequently express EGFR, treatment with small molecules targeting the EGFR signal transduction pathway has proven largely disappointing, thus suggesting that direct immune-mediated targeting of this marker could be more effective (34). Our data indicate that, indeed, expansion of GBM-derived c-CSC may be prevented by ADCC mediated by CD16 158V -CR T cells and anti-EGFR IgG1 mAb.…”
Glioblastoma multiforme (GBM) is the deadliest human brain tumor with a median survival following diagnosis of 14-16 months. Innovative therapeutic approaches are urgently needed. Cancer stem cells (CSC) from GBM resist current chemo-and radiotherapies and can generate recurrent and aggressive tumors. To envisage innovative therapeutic approaches of potential clinical use, we engineered T cells with Fcγ-chimeric receptors (CRs) to elicit antibody-dependent cellular cytotoxicity (ADCC) in the presence of mAbs specific for tumor associated an-
“…For one patient, the cost decreases from 40 to 50% when using only the EGFR2/EGFR3 assay. Moreover, in contrast to FISH, dPCR allows the simultaneous detection of the EGFRvIII variant, which has been shown to be a potential therapeutic target [26]. Lower copy number values observed between EGFR2 and EGFR3 amplicons are very likely explained by the presence of the EGFRvIII variant.…”
Epidermal growth factor receptor (EGFR) amplification and EGFR variant III (EGFRvIII, deletion of exons 2-7) are of clinical interest for glioblastoma. The aim was to develop a digital PCR (dPCR)-based method using locked nucleic acid (LNA)-based hydrolysis probes, allowing the simultaneous detection of the EGFR amplification and EGFRvIII variant. Sixty-two patients were included. An exploratory cohort (n = 19) was used to develop the dPCR assay using three selected amplicons within the EGFR gene, targeting intron 1 (EGFR1), junction of exon 3 and intron 3 (EGFR2) and intron 22 (EGFR3). The copy number of EGFR was estimated by the relative quantification of EGFR1, EGFR2 and EGFR3 amplicon droplets compared to the droplets of a reference gene. EGFRvIII was identified by comparing the copy number of the EGFR2 amplicon to either the EGFR1 or EGFR3 amplicon. dPCR results were compared to fluorescence in situ hybridization (FISH) and next-generation sequencing for amplification; and to RT-PCR-based method for EGFRvIII. The dPCR assay was then tested in a validation cohort (n = 43). A total of 8/19 EGFR-amplified and 5/19 EGFRvIII-positive tumors were identified in the exploratory cohort. Compared to FISH, the EGFR3 dPCR assay detected all EGFR-amplified tumors (8/8, 100%) and had the highest concordance with the copy number estimation by NGS. The concordance between RT-PCR and dPCR was also 100% for detecting EGFRvIII using an absolute difference of 10.8 for the copy number between EGFR2 and EGFR3 probes. In the validation cohort, the sensitivity and specificity of dPCR using EGFR3 probes were 100% for the EGFR amplification detection compared to FISH (19/19). EGFRvIII was detected by dPCR in 8 EGFR-amplified patients and confirmed by RT-PCR. Compared to FISH, the EGFR2/EGFR3 dPCR assay was estimated with a one-half cost value. These results highlight that dPCR allowed the simultaneous detection of EGFR amplification and EGFRvIII for glioblastoma.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.